Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.
16 reports, 3 independent
Updated Sep 8
Gone quiet
Reached 10 outlets in its first 24 hours
- Reports
- 16
- Developments
- 1
- Repetition
- 94%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Also in this story
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Merck announced a landmark moment in vaccine testing, alongside updates regarding personnel at Moderna and Columbia University.
- Moderna combined its vaccine with Merck's Keytruda drug.
- Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.
The entities involved
-
Moderna
American biotechnology company
-
National Cancer Institute
public hospital in Milan dedicated to cancer care
-
Merck
public company in Indonesia
Related events
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Analyst comments on industry trends regarding Moderna's competition in the cancer vaccine market.
- GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.
- Moderna and Merrill jointly developed skin cancer vaccine trials.
- A market rally was observed in the biotech sector, driven by positive cancer vaccine news, causing Eli Lilly shares to rise.